Myasthenia gravis

Last updated: December 12, 2025

Myasthenia gravis

Term 1

Term 1

Glycolysis
Electron transport chain and oxidative phosphorylation
Glycogen metabolism
Citric acid cycle
Gluconeogenesis
Pentose phosphate pathway
Fatty acid oxidation
Fatty acid synthesis
Cholesterol metabolism
Ketone body metabolism
Amino acids and protein folding
Enzyme function
Amino acid metabolism
Nitrogen and urea cycle
Protein structure and synthesis
Cellular structure and function
Cell membrane
Selective permeability of the cell membrane
Extracellular matrix
Cell-cell junctions
Endocytosis and exocytosis
Osmosis
Resting membrane potential
Cell signaling pathways
Nuclear structure
Cytoskeleton and intracellular motility
Inflammation
Ischemia
Free radicals and cellular injury
Atrophy, aplasia, and hypoplasia
Metaplasia and dysplasia
Hyperplasia and hypertrophy
Oncogenes and tumor suppressor genes
DNA structure
Transcription of DNA
Translation of mRNA
DNA replication
DNA damage and repair
Cell cycle
Mitosis and meiosis
DNA mutations
Mendelian genetics and punnett squares
Inheritance patterns
Gene regulation
Epigenetics
Independent assortment of genes and linkage
Polymerase chain reaction (PCR) and reverse-transcriptase PCR (RT-PCR)
Gel electrophoresis and genetic testing
DNA cloning
Galactosemia
Homocystinuria
Phenylketonuria (NORD)
Tay-Sachs disease (NORD)
Pyruvate dehydrogenase deficiency
Kwashiorkor
Marasmus
Folate (Vitamin B9) deficiency
Vitamin B12 deficiency
Down syndrome (Trisomy 21)
Patau syndrome (Trisomy 13)
Edwards syndrome (Trisomy 18)
Turner syndrome
Klinefelter syndrome
Ehlers-Danlos syndrome
Marfan syndrome
Myocardial infarction
Iron deficiency anemia
Alpha-thalassemia
Beta-thalassemia
Sickle cell disease (NORD)
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Autoimmune hemolytic anemia
Introduction to pharmacology
Pharmacokinetics: Drug metabolism
Cystic fibrosis
Osteomalacia and rickets
Septic arthritis
Rheumatoid arthritis
Juvenile idiopathic arthritis
Gout
Osteoarthritis
Osteoporosis
Diabetes mellitus
Gestational diabetes
Lower urinary tract infection
Insomnia
Major depressive disorder
Selective serotonin reuptake inhibitors
Serotonin and norepinephrine reuptake inhibitors
Suicide
Generalized anxiety disorder
Anxiety disorders: Clinical
Social anxiety disorder
Panic disorder
Obsessive-compulsive disorder
Endocrine system anatomy and physiology
Acromegaly
Insulin
Glucagon
Growth hormone deficiency
Hunger and satiety
Wound healing
Anticoagulants: Direct factor inhibitors
Platelet plug formation (primary hemostasis)
Cartilage structure and growth
Oxygen-hemoglobin dissociation curve
Karyotyping
Fluorescence in situ hybridization
Bone histology
Nasal cavity and larynx histology
Adrenal gland histology
Bronchioles and alveoli histology
Cartilage histology
Thyroid and parathyroid gland histology
Pancreas histology
Skeletal muscle histology
Trachea and bronchi histology
Arteriole, venule and capillary histology
Sympathetic nervous system
Parasympathetic nervous system
Nervous system anatomy and physiology
Cholinergic receptors
Muscle contraction
Muscle weakness: Clinical
Skin anatomy and physiology
Psoriasis
Epidermolysis bullosa
Albinism
Vitiligo
Acne vulgaris
Skin cancer
Alopecia areata
Sunburn
Actinic keratosis
Burns
Cell-mediated immunity of CD4 cells
Cell-mediated immunity of natural killer and CD8 cells
Pneumonia
Vaccinations
Introduction to the immune system
Monoclonal antibodies
Antibody classes
B-cell activation, differentiation, and contraction
B-cell development
Body temperature regulation (thermoregulation)
Cluster headache
Tension headache
Migraine
Meningitis
Brain abscess
Hashimoto thyroiditis
Thyroid hormones
Euthyroid sick syndrome
Human development week 2
Human development days 4-7
Human development week 3
Ectoderm
Mesoderm
Endoderm
Adrenal cortical carcinoma
Primary adrenal insufficiency
Congenital adrenal hyperplasia
Adrenocorticotropic hormone
Synthesis of adrenocortical hormones
Ornithine transcarbamylase deficiency
Neuron action potential
Fats and lipids
Innate immune system
T-cell development
Cytokines
T-cell activation
MHC class I and MHC class II molecules
B- and T-cell memory
Graves disease
Asthma
Polymerase chain reaction (PCR) and reverse-transcriptase PCR (RT-PCR)
Williams syndrome
Calcium pyrophosphate deposition disease (pseudogout)
Osteomalacia
Lipid-lowering medications: Statins
Hyperlipidemia
Blood brain barrier
Cerebrospinal fluid
Guillain-Barre syndrome
Raynaud phenomenon
Myasthenia gravis
Muscular dystrophy
Subarachnoid hemorrhage
Diabetic retinopathy
Hypopituitarism
Hyperpituitarism
Kallmann syndrome
Phosphate, calcium and magnesium homeostasis
Parathyroid hormone
Calcitonin
Vitamin D
Hypercalcemia
Hypocalcemia
Hyperparathyroidism
Hypothyroidism
Hyperthyroidism
Cushing syndrome

Transcript

Watch video only

Myasthenia gravis comes from the Greek word ‘myasthenia’, meaning muscle weakness; and the Latin word ‘gravis’, meaning severe. So, myasthenia gravis is an autoimmune condition that causes serious muscle weakness.

First, let's focus on physiology and how muscles normally work. Whether you’re reaching for a slice of pizza or sinking that perfect shot in basketball, it all starts in the brain. The upper motor neuron of the cerebral cortex fires an action potential down the spinal cord to activate lower motor neurons. Next, lower motor neurons pick up these signals and pass them along their axons toward terminal branches and axon terminals, all the way to skeletal muscle fibers.

This communication site between the lower motor neuron and the skeletal muscle fiber is known as the neuromuscular junction, which consists of three main parts. First, there’s the presynaptic membrane, which is the axon terminal of the lower motor neuron packed with acetylcholine vesicles. Acetylcholine is actually the neurotransmitter that enables muscle contraction. Next, there’s the postsynaptic membrane, which is the membrane of the skeletal muscle fiber, rich in nicotinic acetylcholine receptors.

Finally, this tiny space between two membranes is called the synaptic cleft and contains the enzyme acetylcholine esterase.

Now, the arrival of the action potential at the axon terminal triggers the opening of voltage-gated calcium channels in the presynaptic membrane, allowing calcium ions to rush in. This triggers the acetylcholine vesicles to fuse with the presynaptic membrane and release acetylcholine into the synaptic cleft. Once inside the cleft, acetylcholine moves across to bind nicotinic acetylcholine receptors on the postsynaptic membrane. Eventually, this binding triggers the muscle cell to depolarize, setting off a chain of intracellular events that lead to contraction. Once the contraction is over, acetylcholine is broken down by acetylcholine esterase, allowing the muscle to relax and prepare for the next signal.

In myasthenia gravis, the immune system produces antibodies that disrupt the normal function of nicotinic acetylcholine receptors. Now, there are three types of autoantibodies. First, we have blocking antibodies, which bind and block acetylcholine receptors, so acetylcholine can’t activate them. Next, there are binding antibodies, which bind the receptors and activate the complement system, eventually destroying them. Finally, the third type includes modulating antibodies, which bind the receptors and trigger the muscle cell to pull the entire receptor inside.

As more receptors are blocked, destroyed, or removed from the postsynaptic membrane, it becomes harder for muscles to receive signals, leading to muscle weakness.

But that's not all. Sometimes, the immune system does not directly attack the acetylcholine receptors. Instead, it targets other important proteins that help neuromuscular junctions work properly, like Muscle Specific Kinase and Lipoprotein Related Protein 4. When they are disrupted, the connection between nerves and muscles becomes unstable or weak, making it even harder for signals to reach the muscle and causing further muscle weakness.

Now, several risk factors contribute to myasthenia gravis, including thymic abnormalities and genetics. In thymic hyperplasia, the thymus enlarges and forms reactive B-cell follicles that produce autoantibodies. Next up is thymoma, which is a tumor that arises from the epithelial cells of the thymus. Both conditions can cause the thymus to misguide the immune system into attacking acetylcholine receptors.

Next up are genetic factors. Certain HLA subtypes, which are genes that help control the immune system, can make someone more likely to develop autoimmune conditions like myasthenia gravis. Moreover, myasthenia gravis often shows up alongside other autoimmune diseases, such as thyroiditis, lupus, or rheumatoid arthritis.

Now, moving to clinical manifestations. As the immune system blocks, destroys or removes receptors from the postsynaptic membrane, muscles have a hard time receiving signals. Ultimately this leads to muscle weakness and fatigue, which is more pronounced in the proximal muscles.

Remember when you were a kid and spent the whole day in the backyard shooting basketballs? Imagine that after a few throws your muscles start to feel weak. You’d have to stop and rest before you could keep playing. Well, that’s what it’s like for someone with myasthenia gravis. Their muscles get tired quickly, even with simple things like brushing their teeth or combing their hair.

Key Takeaways

Myasthenia gravis is an autoimmune disease, specifically a type II hypersensitivity disorder, which is characterized by autoantibodies against nicotinic acetylcholine receptors on the surface of muscle cells.

The antibodies block the receptors which means the signal to contract isn't received. Those antibodies also activate the complement pathway which leads to muscle cell destruction.

Symptoms can range from mild to severe and may include drooping eyelids, difficulty speaking or swallowing, and muscle weakness in the arms and legs. Treatment involves immunosuppressive drugs like prednisolone, and acetylcholinesterase inhibitors like neostigmine. The purpose is to reduce the immune system's attack on the muscle and to increase muscle strength.

Sources

  1. "Robbins & Kumar Basic Pathology. Available from: ClinicalKey Student, (11th Edition). " Elsevier Limited (UK) (2022. Page 718-720 )
  2. "Conn's Current Therapy 2025. Available from: ClinicalKey Student" Elsevier Limited (UK) (2024. Page 806-811 )
  3. "Crush Step 1 E-Book. Available from: ClinicalKey Student, (3rd Edition)" Elsevier Limited (UK) (2023. Page 461-471 )